TWI852980B - Ｌ ｉ ｌ ｒ ｂ ３ 結合分子及其用途 - Google Patents

Ｌ ｉ ｌ ｒ ｂ ３ 結合分子及其用途 Download PDF

Info

Publication number
TWI852980B
TWI852980B TW109101527A TW109101527A TWI852980B TW I852980 B TWI852980 B TW I852980B TW 109101527 A TW109101527 A TW 109101527A TW 109101527 A TW109101527 A TW 109101527A TW I852980 B TWI852980 B TW I852980B
Authority
TW
Taiwan
Prior art keywords
seq
antibody
lilrb3
amino acid
antibodies
Prior art date
Application number
TW109101527A
Other languages
English (en)
Chinese (zh)
Other versions
TW202031685A (zh
Inventor
理查 布羅克
賈貴林 梅森
馬克 布雷
Original Assignee
大學健康網絡
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大學健康網絡 filed Critical 大學健康網絡
Publication of TW202031685A publication Critical patent/TW202031685A/zh
Application granted granted Critical
Publication of TWI852980B publication Critical patent/TWI852980B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109101527A 2019-01-18 2020-01-16 Ｌ ｉ ｌ ｒ ｂ ３ 結合分子及其用途 TWI852980B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962794064P 2019-01-18 2019-01-18
US62/794,064 2019-01-18

Publications (2)

Publication Number Publication Date
TW202031685A TW202031685A (zh) 2020-09-01
TWI852980B true TWI852980B (zh) 2024-08-21

Family

ID=71612981

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109101527A TWI852980B (zh) 2019-01-18 2020-01-16 Ｌ ｉ ｌ ｒ ｂ ３ 結合分子及其用途

Country Status (14)

Country Link
US (1) US12404327B2 (enExample)
EP (1) EP3911680A4 (enExample)
JP (1) JP7631203B2 (enExample)
KR (1) KR20210118116A (enExample)
CN (1) CN113454123A (enExample)
AU (1) AU2020209367A1 (enExample)
BR (1) BR112021014102A2 (enExample)
CA (1) CA3126295A1 (enExample)
EA (1) EA202192008A1 (enExample)
IL (1) IL284781A (enExample)
MX (1) MX2021008507A (enExample)
SG (1) SG11202107663UA (enExample)
TW (1) TWI852980B (enExample)
WO (1) WO2020146946A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI832183B (zh) * 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
CN116963747A (zh) * 2020-12-03 2023-10-27 德克萨斯大学体系董事会 用于鉴定lilrb阻断抗体的方法
EP4255451A4 (en) * 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
CN115925941B (zh) * 2022-06-08 2026-04-03 北京科诺信诚科技有限公司 靶向人lilrb4的纳米抗体及其应用
WO2025231127A1 (en) * 2024-05-02 2025-11-06 The Regents Of The University Of California Compositions and methods for intracellular antigen targeting with antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
JP5947727B2 (ja) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
AU2011207253B2 (en) * 2010-01-20 2015-02-12 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
CA2917077A1 (en) 2013-07-03 2015-01-08 University Health Network Antibodies to toso
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
EP3256163A4 (en) * 2015-02-11 2018-10-10 University Health Network Methods and compositions for modulating lilr proteins
CN107660150B (zh) * 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
CA3218106A1 (en) * 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof

Also Published As

Publication number Publication date
BR112021014102A2 (pt) 2021-09-21
US20220089723A1 (en) 2022-03-24
MX2021008507A (es) 2021-09-21
TW202031685A (zh) 2020-09-01
KR20210118116A (ko) 2021-09-29
WO2020146946A1 (en) 2020-07-23
US12404327B2 (en) 2025-09-02
JP2022517809A (ja) 2022-03-10
SG11202107663UA (en) 2021-08-30
CA3126295A1 (en) 2020-07-23
AU2020209367A1 (en) 2021-08-19
JP7631203B2 (ja) 2025-02-18
EA202192008A1 (ru) 2021-10-21
IL284781A (en) 2021-08-31
CN113454123A (zh) 2021-09-28
EP3911680A1 (en) 2021-11-24
EP3911680A4 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
US12404327B2 (en) LILRB3-binding molecules and uses therefor
JP7596298B2 (ja) 免疫応答を調節するためおよび疾患を処置するためのｂｔｌａ結合（ｃｄ２７２）抗体
US20220153834A1 (en) Tsg-6 antibodies and uses therefor
US20240150462A1 (en) Lilrb1 and lilrb2-binding molecules and uses therefor
TWI857009B (zh) Ｆｃｍｒ結合分子及其用途
EA046937B1 (ru) Lilrb3-связывающие молекулы и варианты их применения